Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
TGI-6 in Hepatocellular Carcinoma: NCT06374173 Clinical Landscape Report 2026
15 October 2026
NCT06374173 clinical landscape for Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Eribulin mesylate in Triple Negative Breast Cancer: NCT06382142 Clinical Landscape Report 2026
15 October 2026
NCT06382142 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Elfritatug in Ovarian Cancer: NCT06380816 Clinical Landscape Report 2026
15 October 2026
NCT06380816 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Utidelone in Triple Negative Breast Cancer: NCT06385990 Clinical Landscape Report 2026
15 October 2026
NCT06385990 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Niraparib Tosylate in Glioblastoma Multiforme: NCT06388733 Clinical Landscape Report 2026
15 October 2026
NCT06388733 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
pp65 RNA-LPs Vaccine(University of Florida) in Recurrent Glioblastoma: NCT06389591 Clinical Landscape Report 2026
15 October 2026
NCT06389591 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Toripalimab in Glioblastoma Multiforme: NCT06389526 Clinical Landscape Report 2026
15 October 2026
NCT06389526 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
nL-CHCHD-001 in Amyotrophic Lateral Sclerosis: NCT06392126 Clinical Landscape Report 2026
15 October 2026
NCT06392126 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Eribulin mesylate in Triple Negative Breast Cancer: NCT06387628 Clinical Landscape Report 2026
15 October 2026
NCT06387628 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nerve Growth Factor Encapsulated With 2-methacryloyloxyethyl Phosphorylcholine Nanocapsules(Beijing Tiantan Hospital) in Amyotrophic Lateral Sclerosis: NCT06391645 Clinical Landscape Report 2026
15 October 2026
NCT06391645 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Vγ9Vδ2 T cell(Beijing Tiantan Hospital) in Glioblastoma Multiforme: NCT06396481 Clinical Landscape Report 2026
15 October 2026
NCT06396481 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cadonilimab in Triple Negative Breast Cancer: NCT06401005 Clinical Landscape Report 2026
15 October 2026
NCT06401005 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.